Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial
暂无分享,去创建一个
R. Greil | L. Bullinger | K. Döhner | R. Schlenk | H. Döhner | V. Gaidzik | P. Paschka | M. Heuser | F. Thol | A. Ganser | M. Pfreundschuh | U. Martens | A. Benner | M. Lübbert | W. Fiedler | H. Salih | K. Mayer | G. Heil | J. Krauter | H. Horst | G. Wulf | B. Hertenstein | G. Göhring | M. Girschikofsky | M. Ringhoffer | A. Kündgen | M. Radsak | V. Teleanu | D. Weber | T. Heinicke | E. Lange | D. Kraemer | C. Schwänen | M. Agrawal
[1] C. Bloomfield,et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation , 2017, The New England journal of medicine.
[2] Heather L. Mulder,et al. The genomic landscape of core-binding factor acute myeloid leukemias , 2016, Nature Genetics.
[3] K. Döhner,et al. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study , 2016, Annals of Hematology.
[4] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[5] O. Abdel-Wahab,et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia. , 2016, Blood.
[6] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[7] H. Dombret,et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial , 2015, Haematologica.
[8] Li-li Wang,et al. High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia , 2015, PloS one.
[9] C. Bloomfield,et al. Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance) , 2014 .
[10] R. Greil,et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. , 2014, Blood.
[11] Qiaojun He,et al. Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells. , 2014, Biochemical pharmacology.
[12] K. Döhner,et al. Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? , 2013, Hematology. American Society of Hematology. Education Program.
[13] M. Gertz,et al. Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases , 2013 .
[14] Cedric E. Dos Santos,et al. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents. , 2013, Blood.
[15] R. Hills,et al. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia , 2013, Leukemia.
[16] Qiaojun He,et al. MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia , 2013, PloS one.
[17] L. Bullinger,et al. Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG). , 2013, Blood.
[18] Augustin Ferrant,et al. Cytarabine dose for acute myeloid leukemia. , 2011, The New England journal of medicine.
[19] M. Colombo,et al. Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors , 2011, Oncogene.
[20] Chuanfeng Wu,et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice , 2011, Proceedings of the National Academy of Sciences.
[21] Franz Király,et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Lübbert,et al. Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib , 2010, Leukemia.
[23] J. Pollack,et al. KIT mutations confer a distinct gene expression signature in core binding factor leukaemia , 2010, British journal of haematology.
[24] Axel Benner,et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[25] C. Bloomfield,et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Fröhling,et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia , 2004, Leukemia.
[27] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] R. Verhaak,et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.
[29] R. Tibshirani,et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.
[30] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Laurence L. George,et al. The Statistical Analysis of Failure Time Data , 2003, Technometrics.
[32] S. Fröhling,et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.
[33] J. Downing,et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. , 2002, Cancer cell.
[34] I. Weissman,et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[35] Lisa Garrett,et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia , 1999, Nature Genetics.
[36] J. Downing,et al. Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. , 1998, Blood.
[37] P F Thall,et al. Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.
[38] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[39] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[40] C. Bloomfield,et al. Series THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia , 2016 .
[41] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[42] C. Bokemeyer,et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. , 2006, Cancer research.
[43] R. Gray. A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .